anthonyyazdaniml/gliner-biomed-balanced-curated-corpus huggingface dataset:
The utility model relates to hydrolat eye drops - artificial tears with antiseptic action, particularly to hydrolate eye drops - artificial tears with microbicidal, moisturizing, cleansing and antiallergic action, which finds application in medicine and in particular in ophthalmology. The hydrolat eye drops - artificial tears with antiseptic action represent a hydrolat solution obtained by distillation of fresh rose blossom - R. damascena - rose water, with a composition of 99.1 wt. % rose water and 0.9 wt. % essential extract - rose oil. The hydrolat eye drops - artificial tears with antiseptic action represent a hydrolat solution obtained by distillation of fresh rose blossom - R. damascena - rose water, with a composition of 48.2 wt. % rose water and 1.8 wt. % essential extract - rose oil and 50 wt. % hydrolates, comprising equal wt. % of: Roman chamomile, eyebright, aloe vera, basil, calendula, St. John&#39;s wort, cornflower, rosehip, bilberry, mulberry. The hydrolat eye drops - artificial tears with antiseptic action represent a hydrolat solution obtained by distillation of fresh rose blossom - R. damascena /- rose water with a composition of 48.2 wt. % rose water and 1.8 wt. % essential extract - rose oil and 50 wt. % hydrolates, comprising equal wt. of one or more of the following: Roman chamomile, eyebright, aloe vera, basil, calendula, St. John&#39;s wort, cornflower, rosehip, bilberry, mulberry. The aforementioned hydrolates may contain essential extracts of flowers, fruits, leaves and roots of the plants. The hydrolat eye drops - artificial tears with antiseptic action are easily applicable in the treatment of many eye diseases, such as dry eye syndrome, allergic and bacterial conjunctivitis, keratitis, cataracts, macular degeneration, when putting in and wearing contact lenses, and others in the field of ophthalmology.
A method for veterinary administration of medication to an animal, particularly a horse, is disclosed. The method involves inserting a capsule containing the medication, which is a liquid formulation, into a device connected to a tubular chamber. An atomizer is activated to atomize the medication, producing atomized medication. Before administration, a force is applied to a mask placed over the animal&#39;s muzzle, connected to the chamber. The atomized medication is then delivered to the animal. The liquid formulation, in some instances, comprises cells, cellular byproducts, or cell-derived products such as stem cells or products from human mesenchymal stem cells. This formulation may lack preservatives and may encompass peptides, proteins, growth factors, cytokines, exosomes, and extracellular vesicles. The delivery mechanism may involve deflating an air bladder to convey the atomized medication. The capsule allows for controlled transfer of the medication between chambers within it, facilitated by removing barriers and applying force.
&lt;P&gt;PROBLEM TO BE SOLVED: To provide engineered anti-IL-23p19 antibodies and uses thereof in treatment of inflammatory, autoimmune and proliferactive disorders.  &lt;P&gt;SOLUTION: Engineered antibodies to human IL-23p19 are provided, as well as uses thereof, e.g. in treatment of inflammatory, autoimmune, and proliferative disorders. This invention relates to a binding compound binding with human IL-23p19, e.g. an antibody including a humanized or chimeric recombinant antibody, or a fragment thereof or the like; and contains a binding compound including at least one antibody light chain variable region or a binding fragment thereof, having at least one, two or three of CDR selected from a group consisting of sequence number 81-89.  &lt;P&gt;COPYRIGHT: (C)2011,JPO&amp;INPIT
PURPOSE: To obtain a skin cosmetic containing a guanidine derivative (salt) having a specific structure, capable of exhibiting excellent softening property- imparting effect to corneal layer for a long time, free from stickiness and capable of providing good feeling of use. CONSTITUTION: This cosmetic contains preferably 0.01-20wt.% of a guanidine derivative of formula I or II [A and B are each a 2-8C alkylene; D is a direct bond, CO, etc.; E is H, a lower alkyl; (m) is 1-6; (n) is 0-6; R&lt;1&gt; is H, a lower alkyl, etc.; (l) is 1-10; G is H, phosphate group, etc.) or its salt (preferably guanidinoethoxyethanol, guanidinopropanoic acid, etc.) as an active ingredient. The compound of formula I or II is obtained by reacting, e.g. an amine derivative such as 2-(2-aminoethoxy)ethanol with a guanidylation reagent such as cyanamide. Furthermore, the effect can moreover be enhanced by further blending the cosmetic with 0.01-10wt.% of succinic acid.
A water-in-oil emulsion comprises 1 to 85 wt. per cent of water dispersed in a siloxane copolymer comprising 60 to 95 wt. per cent of &lt;FORM:1021044/C3/1&gt; units, where each R is a monovalent hydrocarbon group at least 60% thereof being C1- 4 alkyl and each a is 0, 1, 2 or 3 and the average a is between 1.9 and 2.5, and 40 to 5 wt. per cent of polyoxyethylene and/or propylene units having at least three oxy atoms and linked to silicon by Si-O-C- linkages with the remaining valencies satisfied by H atoms.  Such copolymers may be obtained by reacting a siloxane of the unit formula &lt;FORM:1021044/C3/2&gt; , where A is a hydrolysable atom or group and y the number of polyoxyalkylene groups to be introduced-with a polyoxyalkylene diol HO(CnH2nO)xH in the presence of a condensation or esterification catalyst.  The emulsions may be used as cosmetic and protective ointments for the skin and may incorporate the additives commonly used in cosmetic and pharmaceutical preparations such as perfumes; pigments; fillers, e.g. zinc or titanium oxide or silicas; sunscreen agents and medicaments.ALSO:A water-in-oil emulsion comprises 1 to 85 wt. % of water dispersed in a siloxane copolymer comprising 60 to 95 wt. % of &lt;FORM:1021044/A5-A6/1&gt; units, where each R is a monovalent hydrocarbon group at least 60% thereof being C1-4 alkyl and each a is 0, 1, 2 or 3 and the average a is between 1.9 and 2.5, and 40 to 5 wt. % of polyoxyethylene and/or propylene units having at least three oxy atoms and linked to silicon by Si-O-C-linkages with the remaining valencies satisfied by H atoms.  Such copolymers may be obtained by reacting a siloxane of the unit formula &lt;FORM:1021044/A5-A6/2&gt; where A is a hydrolysable atom or group and y the number of polyoxyalkylene groups to be introduced-wwith a polyoxyalkylene diol HO(CnH2nO)xH in the pressence of a condensation or esterification catalyst.  The emulsions may be used as cosmetic and protective ointments for the skin and may incorporate the additive commonly used in cosmetic and pharmaceutical preparations such as perfumes; pigments; fillers e.g. zinc or titanium oxide or silicas; sunscreen agents and medicaments.
225,256. Sartory, P. July 26, 1923. Hair-curling appliances. -In the process of permanent hair waving heat is furnished by the local application of materials which react esothermically, such as calcium oxide, strontia, or baryta, and water. The calcium oxide or other material is contained in a jacket 1, Fig. 1, comprising an envelope of fabric or paper divided into pockets by rows 2 of stitching and provided with a flap or extension 3. The jacket is applied to a tress of hair 5, Fig. 3, wound on a curler 6, the flap 3 being first wrapped round the tress. Water is applied to the material in the jacket by a wrapping 7 of cotton wool or the like saturated with water, and the whole is enclosed in a tube 8 which is divided longitudinally, each section having a slotted end plate 10 adapted to embrace the root end of the curler. The sections of the tube are held together by a clip 11 perferably secured to one section. Fig. 7 shows a modification in which the heating pad 1 is arranged as a tubular jacket and is carried on a light perforated tube 13, and is enveloped in an absorbent pad 7. The pad, arranged as shown, may be inserted into a steaming tube 8. Fig. 8, provided with a water inlet 14 connected to a perforated distributing pipe 15. The ligament end of the tube 8 is constructed to form a steam tight joint with a closure 16 mounted on the end of the curler 6. and the other end is provided with an adjustable cap 17 carrying a spring 18 engaging with a shoulder 6a on the end of the curler. If a short pad is used, a split sleeve 19 with lugs 19&lt;a&gt; is provided to retain the pad. The steaming tube 8 may be provided. with a ring to engage a handle to support the tube when manipulated personally, and the inlet tube 14 is conveniently connected to a rubber bulb for forcing water into the pipe 15. Fig. 11 shows a heating jacket&#39; 1, enclosed in an outer covering 20 of waterproof material and provided with a water inlet 14 and a distributing pipe 15, which may be applied to the hair without using a separate steaming tube. One end of the cover 20 is clipped to the hair by means of an adjustable clip 21 and the other end plugged.
&lt;P&gt;PROBLEM TO BE SOLVED: To provide extract of the petals or the like of Rosa rugosa Thunb. as a highly safe natural product for human body, useful against hyperglycemia, diabetes and obesity attributable to meals or the like, and to provide a method for using the extract.  &lt;P&gt;SOLUTION: An α-amylase inhibitor, an α-glucosidase inhibitor and a glucose enteric absorption inhibitor are provided, each being characterized by comprising, as active ingredient, extract of the petals or fruits of Rosa rugosa Thunb. The extract is obtained using water, an organic solvent or hydrous organic solvent as extractant. Uses of these inhibitors are also provided.  &lt;P&gt;COPYRIGHT: (C)2006,JPO&amp;NCIPI
Two patients diagnosed with KLS were treated. One patient had severe KLS that progressed to the equivalent of pediatric Kawasaki Disease Shock Syndrome (KDSS). The second patient had a typical KLS presentation and clinical course. Cytokines and chemokines provide inflammatory signatures in the serum that reflect the polarity of the immune response and the affected cell types. Multiplex ELISA technology was used to define the cytokine milieu in the serum of the two adult HIV patients with KLS during the acute and convalescent phases. Those sera were compared with sera from asymptomatic HIV subjects and a normal serum control. Those comparisons suggest that HIV KLS is a dysfunctional Th2 response to an unknown inciting agent in the vascular wall, and that a multiplex ELISA or similar technology based a limited combination of KLS/KD pathogenesis-related cytokines (IL-6, IL-13, sTNFRII) and endothelial/smooth muscle chemokines (CCL1, CCL2, CxCL11) may provide an objective tool for diagnosing KLS and Kawasaki Disease. Because KD and HIV KLS are the only known &#34;Th2&#34; vasculitidies that spare the lungs (unique clinical presentation) and include plasma cell infiltration of the vascular wall as a prominent histopathologic feature (unique pathophysiology), a diagnostic test based on combinations of the above analytes will be highly specific and therefore clinically useful.
&lt;P&gt;PROBLEM TO BE SOLVED: To provide a spray composition which can be sprayed on the scalp of a thin hair portion to give an appearance having the black and thick hairs to the scalp.  &lt;P&gt;SOLUTION: This spray composition is characterized by comprising (a) 8 wt. % of fine powder having a particle diameter of about 13 μm and comprising [bamboo charcoal] produced from bamboo as a raw material, (b) 25 to 35 wt. % of ethanol as a solvent, and (c) 6 to 24 wt. % of dimethyl ether and 36 to 64 wt. % of liquidized petroleum gas as propellants. The fine powder having a particle diameter of about 13 μm and comprising bamboo charcoal is charged into a spray container together with the solvent and the propellants and then sprayed from the spray container. Thereby, the fine powder having a particle diameter of about 13 μm and comprising the bamboo charcoal can be attached to the scalp and the thin hair, and can give an appearance having black and thick hairs to the scalp. When the fine powder having a particle diameter of about 13 μm and comprising the bamboo charcoal is adhered to the scalp and the thin hair, the hair and the scalp can be cared by the antibacterial and deodorizing properties of the bamboo charcoal, itself.  &lt;P&gt;COPYRIGHT: (C)2005,JPO&amp;NCIPI
Delivery of health information to a patient suffering from a chronic condition is personalized by displaying the health information directly on a customized image of a body. The patient&#39;s medical record, standards of care for the condition, prescribed treatments, and patient input are applied to a generalized health model of a disease to generate a personalized health model of the patient. The personalized health model comprises an HTML file encoding an image map of a body. The body image illustrates the health condition of the individual patient. Preferably, data is collected from health provider sources and stored in a database on a server at a service provider site. The data is processed at the server, and is displayed in the patient&#39;s home using a TV connected to a multimedia processor. The multimedia processor connects the television set to a communications network such as the Internet.
PURPOSE:To provide a hair-treatment composition to be used by adjusting to a specific pH, containing a specific silicone compound and a specific impregnation promoting agent and exhibiting improved effect to prevent the splitting of hair and to keep the gloss of hair. CONSTITUTION:The 1st agent of the objective composition contains 0.01-50wt.% of a compound of formula I or formula II (X is alkali metal, alkaline-earth metal, ammonia, amine or quaternary ammonium salt; (n) is 1-20; (m) is 1-20; n/m&gt;1; (l) is 1-20). The 2nd agent of the composition is an alkali solution optionally containing ammonia or amine to adjust the pH to 8-11. A compound of formula III or formula IV (R is H, lower alkyl, etc.; Y is H or OH; (p), (q) and (r) are 0.5; R3 is 8-18C alkyl) is added in an amount of 0.1-50wt.% to the 1st agent and/or the 2nd agent. The objective two-pack type composition can be produced by properly compounding conventional hair cosmetic components to the agents.
&lt;P&gt;PROBLEM TO BE SOLVED: To provide a medicine having a new action mechanism against diseases such as immunity disorders, etc., and a method necessary for the development of the same.  &lt;P&gt;SOLUTION: This method for screening a substance capable of regulating the activation of cells comprises the evaluation whether a test substance can regulate the formation of micro clusters (MC)(e.g. TCR-containing MC) containing a cell surface receptor capable of forming the cluster, or not. The kit for screening the substance capable of regulating the activation of cells includes an expression vector of a constituting molecule of the MC containing the cell surface receptor capable of forming the cluster, or a T cell introduced with the expression vector. The cell activation-regulating agent contains the substance capable of regulating the formation of the MC containing the cell surface receptor capable of forming the cluster.  &lt;P&gt;COPYRIGHT: (C)2007,JPO&amp;INPIT
PURPOSE:The titled composition effective for atopic dermatitis, inhibiting specifically lipoxygenase and production of 5-HETE, comprising dried powder of &#39;KOGANEBANA&#39; (Scutellaria baicalensis GEORGI) of the family Labiatae or its relative species, or an extract of the powder as an essential component. CONSTITUTION:A composition comprising baicalein shown by the formula I or baicalein shown by the formula II of dried powder of &#39;KOGANEBANA&#39; (Scutellaria baicalensis GEORGI) or its relative species (e.g., Scutellaria viscidula BUXGE, etc.) or an extract of the powder as an active ingredient. This composition can be used any cosmetic composition (e.g., ointment, soap, toilet lotion, cream, etc.), and easily applied at home without indication of doctor. It has no side effect like adrenocortial hormone ointment, inhibits production of 5-HETE, and has improved remedying effect on atopic dermatitis, one form of allergic reactions.
Compsn. contg. a dispersion of lipid vesicles with an aq. core and/or lipid vesicles with an oily core, comprises at least one acidic cpd. which confers a pH of &lt; 5 to the compsn., the lipid membrane of the vesicles having an aq. core contg. neither acidic amphiphilic lipids, nor non-hydrogenated soya lecithin in presence of glycerine is new. The compsn. is an oil-in-water dispersion, and the lipid vesicles disperse the oil in the aq. phase. The aq.-core vesicles include a lipid membrane obtd. from non-ionic and/or ionic amphiphilic lipids. The oil-core vesicles are surrounded by a mono- or oligo-lamellar layer obtd. from at least one lipophilic surfactant with a fatty chain contg. &gt;12C, a hydrophilic surfactant, an ionic amphiphilic lipid selected from neutralised anionic lipids, amphoteric lipids and alkylsulphonyl derivs. and fatty acids, pref. a 16-22C satd. fatty alcohol, associated with a basic agent such as NaOH, triethanolamine, lysine or arginine.
PROBLEM TO BE SOLVED: To obtain a cosmetic by placing a cosmetic preparation in a non- aqueous solvent or a high concentration alcohol into a container which is excellent in appearance and made of a less expensive plastic material stable under a high humidity and a high temperature. SOLUTION: A cosmetic preparation obtained by dissolving, dispersing or emulsifying an active component in a non-aqueous solvent or a high concentration alcohol is placed in a container made of a composite material of a high density polyethylene and a polypropylene. The container is preferably composed of an innermost layer of a high density polyethylene, a middle layer of a high density polyethylene and an outermost layer of a polypropylene. The high concentration alcohol is preferably a liquid containing &gt;=50wt.% of alcohol. The active component is pentadecanoic acid glyceride, a vitamin, their derivatives, a crude drug extract, glycyrrhetinic acid, its derivative, etc. The cosmetic is a hair tonic, a setting agent, a treatment agent or a spot and wrinkle preventing agent.
PURPOSE:To obtain the titled novel plasminogen activator useful as a fibriolytic agent, having improved affinity for fibrin and high thrombus dissolving ability, by cultivating a cell strain derived from human and collecting and purifying the activator from the culture solution. CONSTITUTION:A cell strain (e.g., cell derived from human striated muscle sarcoma) derived from human is cultivated and a culture solution is collected and purified to give a novel plasminogen activator from human tissue having the following physical and chemical properties. Molecular weight: 62,000-73,000. Action and substrate specificity: converting inactive precursor plasminogen into plasmin and dissolving fibrin. Having higher affinity for fibrin than urokinase on the market. Km of synthetic substrate S-2288 is 3.6X10&lt;-4&gt;M, Vmax116mol/min.I.U. Optimum pH: 7-11. Stable pH: 4.5-11. Action suitable temperature: 30-45 deg.C. Temperature resistance: not deactivating under heating for 90min up to 50 deg.C. Isoelectric point: pH7.5-8.0.
299,522. Leonard, V. July 29, 1927. Antiseptics; lotions; medicines for internal use. -An effective bactericidal solution of normal hexyl resorcinol, for sterilizing living tissue surfaces or objects such as surgical and dental instruments or false teeth, is prepared by dissolving the hexyl resorcinol in glycerol and adding water to obtain a clear solution having a very low surface tension. There is an optimum composition of glycerol and water at which the surface tension reaches a minimum value and the germicidal power reaches a maximum. Further addition of water does not precipitate the hexyl resorcinol and only raises the surface tension relatively slightly. As an example, one part of hexyl resorcinol is dissolved in 300 parts by weight of glycerol .and 700 parts of water are added. The clear solution obtained has a surface tension of 3&#39;7 dynes per centimetre. Reference is made in the Specification to the known use of a solution of hexyl resorcinol in olive oil for internal administration. Specifications 9726/94 and 15931/08 are referred to. The Provisional Specification describes the application of the process to such of the higher phenols (such as hexyl resorcinol and its homologues) as are soluble in glycerol, or to mixtures of these higher phenols.
PURPOSE: To obtain an pharmaceutical composition comprising a therapeutically effective amount of glycine B partial agonist or its prodrug thereof as an active ingredient and useful for treating mental diseases. CONSTITUTION: This pharmaceutical composition comprises a therapeutically effective amount of compound or its prodrug thereof as an active ingredient. One or more compounds selected from a compound group of the formula (R&lt;1&gt; is a hydrido, an alkyl, a haloalkyl, etc.; R&lt;2&gt; is a hydrido, an alkyl, aralkyl, etc.; R&lt;3&gt; is a hydrido, an alkyl, a haloalkyl, an alkoxy, etc.) or its salt is used as the compound. The composition has possibility to treatment for acute or chronic phencyclidine (general anesthetic)-induced psychiatric disorder.
The interventional procedure involves the management of BCC with an initial diagnosis based on the deepLive™ device. The imaging is performed by placing the probe tip in contact with the patient\&#39;s skin after applying an immersion oil (paraffin) to the imaging area. The examination lasts only a few minutes and is painless. An integrated dermoscopic targeting system allows the operator to ensure proper positioning of the probe on the lesion and to ensure that the entire lesion has been captured for an accurate diagnosis. The images are displayed in real-time during the examination and directly evaluated by the investigator, who has the option to save images/videos at their discretion. A final evaluation with the deepLive™ device will also be performed during the 1-year follow-up, and intermediate evaluations may also be performed with the deepLive™ device depending on the initial management of BCC.
PURPOSE: A cosmetic composition containing siRNA oligonucleotide is provided to ensure excellent skin whitening effect and to stable penetration efficiency without irritation. CONSTITUTION: A siRNA oligonucleotide which suppresses tyrosinase expression forms a double strand through complementary bond of two strand sequences selected from sequence numbers 1-82. The siRNA oligonucleotide additionally contains an overhang TT sequence at 3&#39;. An external use skin composition contains the siRNA oligonucleotide as an active ingredient. The composition is manufactured in the form of solid perforator formulation. The solid perforator is a micro-needle.
The present invention relates to preparation of drug loaded heterogeneous nanosystems resulting from mixing of two monophasic phases, the non-aqueous phase comprising of active agent/s, polymers, lipids, surfactants, solubilizer/s and other excipients and the aqueous phase comprising of buffers, isotonic solutions, sweetners, flavors and other excipients.The novel technique enables formation of stable colloidal particles with high drug loading and predictable size at the time of use. The invention represents a major step in circumventing the technological challenges in the design of colloidal particles which can remain suspended for at least 4h maintaining an effective average particle size of &lt;1μm. The unique delivery system makes part of the active agent/s readily bioavailable and part of the agent is present within the polymeric matrix. The invention is applicable to agent/s that contains electrical group, as the particles are formed due to electrostatic interaction. The novel technique avoids use of organic solvent and can reduce energy requirements compared to the conventional preparation methods. The invention is aimed at the overall improvement of therapeutic efficacy, enhance solubility, enhance oral bioavailability and rapid dissolution for in vivo delivery of the BCS class agent/s. The heterogeneous nanosystems /compositions produced according to the invention can be useful in drug delivery, imaging and diagnosis and can be administered by oral and parenteral route.